Zealthy review

Zealthy: listed only so a reader can see why it ranks last

Zealthy advertises among the lowest disclosed compounded prices this board tracks — $135/month for semaglutide, $225/month for tirzepatide. Read the two items below before that number means anything.

The FTC and DOJ receivership petition

In April 2026 the FTC and DOJ asked a federal court to place Zealthy in receivership and freeze its assets, alleging deceptive disclosures, obstructive cancellation practices, and review manipulation. The same complaint alleges misuse of clinicians' NPI numbers to issue prescriptions without their knowledge or consent. In the government's own words, Zealthy is "actively deceiving telehealth patients, endangering their safety, and raiding their bank accounts." These are allegations, not adjudicated findings, and the case remains open. They are also serious enough that a mother evaluating this provider should read the filing herself before signing up for anything.

A separate, earlier FDA warning letter

Before the federal receivership action, Zealthy carried its own regulatory history: an FDA warning letter dated 9 September 2025, addressed to FitRX, LLC dba Zealthy and naming getzealthy.com, over the unlawful sale of unapproved and misbranded compounded semaglutide. That letter and the 2026 FTC/DOJ action are two separate matters, both attached to the same company, months apart.

What the low price does not tell a mother

Zealthy is compounded only — not an FDA-approved finished product — and its public materials carry no postpartum, breastfeeding, or PCOS-specific framing. Program and membership fees can also move the real all-in cost above the headline figure. None of that is the central issue here; the federal action and the warning letter are. A price this far below the field is not, by itself, evidence of anything. In this specific case, it sits alongside two separate government findings that are, and a low sticker price is exactly the kind of thing the FDA's own telehealth red-flag guidance tells patients to treat as a caution sign rather than a reason to sign up faster.

Why we still publish a review of a company under federal action

A mother searching for Zealthy by name deserves to find what a regulator found, not a gap where a review used to be. Delisting it quietly would leave the search results to third-party sites with less complete information, or to Zealthy's own marketing. Keeping the entry, with the receivership petition and the warning letter stated plainly and dated, is the more useful outcome for the reader this board exists for — even though nothing about the entry recommends starting treatment here while the case is open.

The bottom line

Zealthy stays on this board for the same reason every provider does: transparency serves a reader better than silence. It is not a recommendation. While the federal case remains open and with a September 2025 FDA warning letter on the record, a mother has better, better-documented options on this list — starting with our #1 pick, CoreAge Rx.